Juvenile dermatomyositis: Extramuscular manifestations and their management

Current Opinion in Rheumatology

Volumn 21, Issue 6, 2009, Pages 575-580

  Lowry, Clodagh A ^a   Pilkington, Clarissa A ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b Department of Rheumatology   (United Kingdom)

Author keywords

Calcinosis; Extramuscular manifestations; Juvenile dermatomyositis; Skin assessment skin disease

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; FLUCLOXACILLIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ARTHRALGIA; ARTHRITIS; CALCINOSIS; CATARACT; CLINICAL TRIAL; CONTRACTURE; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG MEGADOSE; DYSPHAGIA; DYSPHONIA; DYSPNEA; FACE RASH; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LETHARGY; LIPODYSTROPHY; LOW DRUG DOSE; LYMPHADENOPATHY; MENTAL DISEASE; MOUTH ULCER; MYALGIA; MYOSITIS; PAPULE; PERICARDITIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RASH; RAYNAUD PHENOMENON; REVIEW; SKIN CALCIFICATION; SKIN ULCER;

ARTHRITIS; AUTOANTIBODIES; CALCINOSIS; CHILD; DERMATOMYOSITIS; EYE; GASTROINTESTINAL TRACT; HEART; HUMANS; LUNG; SKIN;

EID: 70349789680     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328331927e     Document Type: Review

References (45)

1. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34:732-736.
2. Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53:166-172.
3. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371:2201-2212.
4. Dugan EM, Huber AM, Miller FW, Rider LC, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15:2.
5. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 years. Rheumatology 2006; 45:1255-1260.
6. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25:126-139.
7. Saygi S, Alehan F, Baskin E, et al. Juvenile dermatomyositis presenting with anasarca. J Child Neurol 2008; 23:1353-1356.
8. Mitchell JP, Dennis GJ, Rider LG. Juvenile dermatomyositis presenting with anasarca: a possible indicator of severe disease activity. J Pediatr 2001; 138:942-945.
9. Bingham A, Mamyrova G, Rother KI, et al., Childhood Myositis Heterogeneity Study Group. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87:70-86.
10. Christen-Zaech S, Seshadri R, Sundberg J, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58:571-576.
11. Rider LG, Atkinson JC. Gingival and periungual vasculopathy of juvenile dermatomyositis. N Engl J Med 2009; 360:e21.
12. Germani P, Walling HW, Lewis J, et al. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157:637-644.
13. Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007; 17:413-417.
14. Pachman LM, Cooke N. Juvenile dermatomyositis clinical and immunological study. J Pediatr 1980; 96:226-229.
15. Tosan A, Serdaroglu G, Aslan MT, et al. Severe juvenile dermatomyositis: two patients complicated with extra musculocutaneous involvement. Rheumatol Int 2006; 26:1040-1043.
16. Rider LG, Miller FW, Targoff IN. Myositis specific autoantibodies (MSA) in children: a broadened spectrum of juvenile myositis [abstract]. Arthritis Rheum 1993; 36:S258.
17. Kobayashi I, YamadaM,Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporine A. Rheumatology (Oxford) 2003; 42:371-374.
18. Zeller V, Cohen P, Prieur A, Guillevin L. Cyclosporin A therapy in refractory juvenile dermatomyositis: Experience and long term follow up of 6 cases. J Rheumatol 1996; 23:1424-1427.
19. Karaca NE, Aksu G, Yeniay BS, Kutukcular N. Juvenile dermatomyositis with a rare and remarkable complication: sinus bradycardia. Rheumatol Int 2006; 27:179-182.
20. Stefanski JC, Shetty AK. Abdominal pain in a girl with juvenile dermatomyositis. Clin Pediatr 1998; 37:561-563.
21. Braunstein EM, White SJ. Pneumatosis intestinalis in dermatomyositis. Br J Radiol 1980; 53:1011-1012.
22. McCann LJ, Garay SM, Ryan MM, et al. Oropharyngeal dysphagia in juvenile dermatomyositis: an evaluation of videofluroscopy swallow study changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007; 46:1363-1366.
23. Pachman LM. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 1995; 42:1071-1098.
24. Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43:541-549.
25. Rider LG. Calcinosis in JDM: pathogenesis and current therapies. Pediatr Rheumatol Online J 2003; 1:119-133.
26. Blane CE, White SJ, Braunstein EM, et al. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol 1984; 142:397-400.
27. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103:882-888.
28. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43:2368-2377.
29. Pachman LM, Veis A, Stock S, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum 2006; 54:3345-3350.
30. Gunawardena H, Wedderburn LR, North J, et al., Juvenile Dermatomyositis Research Group UK. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47:324-328.
31. Gunawardena H, Wedderburn LR, Chinoy H, et al., Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
32. Maillard SM, Jones R, Owens CM, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005; 53:558-564.
33. Rouster-Stevens KA, Gursahaney A, Ngai K-L, et al. Pharmacokinetic study of oral prednisolone compared with intravenous methyl-prednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58:222-226.
34. Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52:3570-3578.
35. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47:505-511.
36. Pediatric Rheumatology INternational Trials Organization. Juvenile dermatomyositis trial. http://www.printo.it/project-ongoing-detail.asp? ProjectID=14.
37. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45:1255-1260.
38. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19:138-141.
39. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877-880.
40. Oddis C, Reed AM. Rituximab in myositis (RIM) study. http://www.edc.gsph. pitt.edu/rimstudy/ [Accessed 1 November 2007].
41. Isenberg D, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004; 43:49-54.
42. Ruperto N, Ravelli A, Pistorio A, et al., Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59:4-13.
43. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49:7-15.
44. Carroll CL, Lang W, Snively B, et al. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008; 158:345-350.
45. Huber AM, Dugan EM, Lachenbruch PA, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile der matomyositis. Arthritis Rheum 2008; 59:214-221.